Actively Recruiting
Comparing Prasugrel Plus Low-Dose Aspirin to High- and Low-Dose Aspirin Alone for Three Months Following Coronary Artery Bypass Grafting in Chronic Coronary Disease OPTIMUS-CABG Trial
Led by Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o. · Updated on 2026-10-27
1703
Participants Needed
18
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of prasugrel plus low-dose aspirin compared to high-dose aspirin alone and low-dose aspirin alone in patients with stable coronary artery disease chronic coronary syndrome who have undergone coronary artery bypass grafting CABG. This phase 3, multicenter, randomized trial aims to assess graft failure and other health outcomes related to these antiplatelet therapies over a 12-month period. Participants will be randomly assigned to one of three groups prasugrel 10 mg plus low-dose aspirin 75 mg daily, high-dose aspirin 300 mg daily, or low-dose aspirin 75 mg daily. The treatment period lasts for three months, after which all participants will continue low-dose aspirin alone. The trial compares these regimens to determine their effects on graft failure and other cardiovascular events. During the study, participants will be monitored for graft failure incidence at 12 months and other outcomes such as ischemic and bleeding events, as well as quality of life over 12 and 60 months. Assessments include clinical follow-ups and evaluations to track adherence and safety. The total study duration covers up to five years to observe long-term effects after CABG surgery.
CONDITIONS
Brief Title
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
Research Team
A
Aleksandra Pawlik
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here